MOTIVATION: Integrating omics data analysis with publicly available databases is crucial for unravelling complex biological mechanisms. However, this integration process is often intricate and time-consuming due to the diversity and complexity of the data involved. Achieving consistent harmonization across data types is challenging when managing disparate formats and sources. To address these issues, we introduce pyBiodatafuse, a query-based Python tool designed to integrate biomedical databases. This tool establishes a modular framework that simplifies data wrangling, enabling the creation of context-specific knowledge graphs (KGs) while supporting graph-based analyses. RESULTS: We developed a pipeline for generating context-specific knowledge graphs dynamically, allowing users to create KGs on the fly from a set of gene or metabolite identifiers. pyBiodatafuse features a user-friendly interface that streamlines this process, making it accessible even to researchers without extensive computational expertise. Additionally, the tool offers plugins for widely used platforms such as Cytoscape, Neo4j, and GraphDB, enabling local hosting of resulting property and RDF graphs. This versatility ensures that generated KGs can be efficiently utilized within diverse research workflows. To demonstrate its potential, we used pyBiodatafuse to create a graph for post-COVID syndrome using differential gene expression data, showcasing its ability to build adaptable and context-specific knowledge representations. Thus, pyBiodatafuse sets the stage for streamlined data integration, empowering researchers to focus on discovery and analysis without being hindered by data management complexities. AVAILABILITY AND IMPLEMENTATION: pyBiodatafuse is open-source, with its source code and PyPi package available at https://github.com/BioDataFuse/pyBiodatafuse and https://pypi.org/project/pyBiodatafuse/. The user interface can be accessed at https://biodatafuse.org/. Additionally, a release has been made on Zenodo at https://doi.org/10.5281/zenodo.18468942.

MOTIVATION: Knowledge graphs (KGs) in life sciences have become an important application of systems biology as they delineate complex biological and pathophysiological phenomena. They are composed of biological and chemical entities represented with standard ontologies to comply with Findable, Accessible, Interoperable and Reusable (FAIR) principles. Alongside serving as a graph database, KGs hold the potential to address complex scientific queries and facilitate downstream analyses. However, the process of constructing KGs is expensive and time consuming as it primarily relies on manual curation from published literature and experimental data. The existing text-mining workflows are still in their infancy and fail to achieve the accuracy and reliability of manual curation. RESULTS: Knowledge graph generator (KGG) is an automated workflow for representing chemotype and phenotype of diseases and medical conditions. It embeds the underlying schema of curated databases such as OpenTargets, Uniprot, ChEMBL, Integrated Interactions Database and GWAS Central resembling a clockwork-esque mechanism. The resultant KG is a comprehensive and rational assembly of disease-associated entities such as proteins, protein-related pathways, biological processes and functions, genetic variants, chemicals, mechanism of actions, assays and adverse effects. As use cases, we have used KGs to identify shared entities for possible link of comorbidity and compared them with KGs from other sources. We have also demonstrated a use case of identifying putative new targets and repurposing drug candidates in Parkinson's Disease. Lastly, we have developed reusable workflows to explore drug-likeness of chemicals and identify structures of proteins. AVAILABILITY AND IMPLEMENTATION: The resources and codes for KGG are publicly available at: https://github.com/Fraunhofer-ITMP/kgg.

MOTIVATION: Drug discovery practitioners in industry and academia use semantic tools to extract information from online scientific literature to generate new insights into targets, therapeutics and diseases. However, due to complexities in access and analysis, patent-based literature is often overlooked as a source of information. As drug discovery is a highly competitive field, naturally, tools that tap into patent literature can provide any actor in the field an advantage in terms of better informed decision-making. Hence, we aim to facilitate access to patent literature through the creation of an automatic tool for extracting information from patents described in existing public resources. RESULTS: Here, we present PEMT, a novel patent enrichment tool, that takes advantage of public databases like ChEMBL and SureChEMBL to extract relevant patent information linked to chemical structures and/or gene names described through FAIR principles and metadata annotations. PEMT aims at supporting drug discovery and research by establishing a patent landscape around genes of interest. The pharmaceutical focus of the tool is mainly due to the subselection of International Patent Classification codes, but in principle, it can be used for other patent fields, provided that a link between a concept and chemical structure is investigated. Finally, we demonstrate a use-case in rare diseases by generating a gene-patent list based on the epidemiological prevalence of these diseases and exploring their underlying patent landscapes. AVAILABILITY AND IMPLEMENTATION: PEMT is an open-source Python tool and its source code and PyPi package are available at https://github.com/Fraunhofer-ITMP/PEMT and https://pypi.org/project/PEMT/, respectively. SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online.

Recent advances in Knowledge Graphs (KGs) and Knowledge Graph Embedding Models (KGEMs) have led to their adoption in a broad range of fields and applications. The current publishing system in machine learning requires newly introduced KGEMs to achieve state-of-the-art performance, surpassing at least one benchmark in order to be published. Despite this, dozens of novel architectures are published every year, making it challenging for users, even within the field, to deduce the most suitable configuration for a given application. A typical biomedical application of KGEMs is drug-disease prediction in the context of drug discovery, in which a KGEM is trained to predict triples linking drugs and diseases. These predictions can be later tested in clinical trials following extensive experimental validation. However, given the infeasibility of evaluating each of these predictions and that only a minimal number of candidates can be experimentally tested, models that yield higher precision on the top prioritized triples are preferred. In this paper, we apply the concept of ensemble learning on KGEMs for drug discovery to assess whether combining the predictions of several models can lead to an overall improvement in predictive performance. First, we trained and benchmarked 10 KGEMs to predict drug-disease triples on two independent biomedical KGs designed for drug discovery. Following, we applied different ensemble methods that aggregate the predictions of these models by leveraging the distribution or the position of the predicted triple scores. We then demonstrate how the ensemble models can achieve better results than the original KGEMs by benchmarking the precision (i.e., number of true positives prioritized) of their top predictions. Lastly, we released the source code presented in this work at https://github.com/enveda/kgem-ensembles-in-drug-discovery.

Network-based approaches are becoming increasingly popular for drug discovery as they provide a systems-level overview of the mechanisms underlying disease pathophysiology. They have demonstrated significant early promise over other methods of biological data representation, such as in target discovery, side effect prediction and drug repurposing. In parallel, an explosion of -omics data for the deep characterization of biological systems routinely uncovers molecular signatures of disease for similar applications. Here, we present RPath, a novel algorithm that prioritizes drugs for a given disease by reasoning over causal paths in a knowledge graph (KG), guided by both drug-perturbed as well as disease-specific transcriptomic signatures. First, our approach identifies the causal paths that connect a drug to a particular disease. Next, it reasons over these paths to identify those that correlate with the transcriptional signatures observed in a drug-perturbation experiment, and anti-correlate to signatures observed in the disease of interest. The paths which match this signature profile are then proposed to represent the mechanism of action of the drug. We demonstrate how RPath consistently prioritizes clinically investigated drug-disease pairs on multiple datasets and KGs, achieving better performance over other similar methodologies. Furthermore, we present two case studies showing how one can deconvolute the predictions made by RPath as well as predict novel targets.

SUMMARY: The COVID-19 crisis has elicited a global response by the scientific community that has led to a burst of publications on the pathophysiology of the virus. However, without coordinated efforts to organize this knowledge, it can remain hidden away from individual research groups. By extracting and formalizing this knowledge in a structured and computable form, as in the form of a knowledge graph, researchers can readily reason and analyze this information on a much larger scale. Here, we present the COVID-19 Knowledge Graph, an expansive cause-and-effect network constructed from scientific literature on the new coronavirus that aims to provide a comprehensive view of its pathophysiology. To make this resource available to the research community and facilitate its exploration and analysis, we also implemented a web application and released the KG in multiple standard formats. AVAILABILITY AND IMPLEMENTATION: The COVID-19 Knowledge Graph is publicly available under CC-0 license at https://github.com/covid19kg and https://bikmi.covid19-knowledgespace.de. SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online.